Endometrial carcinoma associated with breast carcinoma. Low incidence with tamoxifen use

Cancer

Volumn 77, Issue 10, 1996, Pages 2058-2063

  Cuenca, Rosa E ^a   Giachino, Juan ^a   Arredondo, Mark A ^a   Hempling, Ronald ^a   Edge, Stephen B ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Breast carcinoma; Endometrial carcinoma; Endometrial carcinoma risk; Incidence; Tamoxifen; Tamoxilen adverse effects

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; DISEASE ASSOCIATION; DRUG EFFECT; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; REGISTRIES; RISK FACTORS; TAMOXIFEN; UNITED STATES;

EID: 0029964446     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2058::AID-CNCR14>3.0.CO;2-U     Document Type: Article

References (27)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 74,000 women (Part I). Lancet 1992;339:1-15.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 74,000 women (Part II). Lancet 1992;339:71-85.
3. CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988;57:604-7.
4. Fisher B, Costantino J, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. A randomized tiral evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 1989;320:479-84.
5. Fornander T, Rutzvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancer. Lancet 1989; 1:117-20.
6. Fornander T, Hellstrom AC, Moberger B. Descriptive clinico-pathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993;85(22):1850-5.
7. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11(3):485-90.
8. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 [see comments]. J Natl Cancer Inst 1994;86(7):527-37.
9. Deligdisch L. Effects of hormone therapy on the endometrium. [review]. Mod Pathol 1993;6(1):94-106.
10. Rullo S, Tagliaferri T, Bandiera F, Fiorelli C, Felici A, Piccioni MG, et al. Uterine changes during tamoxifen therapy. Clin Exp Obstet Gynecol 1993;20(2):116-9.
11. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994;170:447-51.
12. Uziely B, Lewin A, Brufman G, Dorembus D, Mor-Yosef S. The effect of tamoxifen on the endometrium. Breast Cancer Res Treat 1993;26(1):101-5.
13. Ferrazzi E, Cartei G, Mattarazzo R, Fiorentino M. Oestrogen-like effect of tamoxifen on vaginal epithelium. BMJ 1977; 1:1351-2.
14. Boccardo F, Bruzzi P, Rugagotti A, Nicolo G, Russo R. Estrogen-like action of tamoxifen on vaginal epithelium in breast oncology patients. Oncology 1981;38:281-5.
15. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer [see comments]. Lancet 1994;343:448-52.
16. Henderson IC. Should tamoxifen use be curtailed because of the risk of endometrial cancer? Breast Diseases: A Year Book Quarterly 1994;5:18-23.
17. Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 1992;31(2):259-63.
18. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83:1013-7.
19. Seoud MA, Johnson J, Weed JC Jr. Gynecologic tumors in tamoxifen-treated women with breast cancer [review]. Obstet Gynecol 1993;82(2):165-9.
20. Altaras MM, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol 1993; 49(2):255-8.
21. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13:513-29.
22. Baum M, Odling-Smee W, Houghton J, Riley D, Taylor H. Endometrial cancer during tamoxifen therapy. Lancet 1994;343:1291.
23. Hindle WH. Tamoxifen therapy and the endometrium: gynecologic considerations. Breast Diseases: A Year Book Quarterly 1994;5:24-6.
24. Lahti E, Guillermo B, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-4.
25. Cohen I, Rosen DJ, Shapira J, Cordoba M, Gilboa S, Altaras MM, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994;52(2):185-90.
26. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-21.
27. Kurjak A, Shalan H, Sosic A, Benic S, Zudenigo D, Kupesic S, et al, Endometrial carcinoma in postmenopausal women: evaluation by transvaginal color doppler ultrasonography. Am J Obstet and Gynecol 1993;169:1597-603.